Innovative Research Pipeline in Oncology, Inflammatory, and infectious diseases
Discover our pioneering research pipeline with over 25 applications, integrating breath analysis in both real-world evidence studies and clinical trials. Partner with us to elevate your research in oncology, inflammatory, and infectious diseases using SpiroNose’s advanced breath diagnostics technology.
Scientific Collaborations
At Breathomix, our collaborations with leading clinical centers worldwide—spanning the EU, Australia, North America, and South Africa—form the backbone of our research and development. By partnering with renowned hospitals and research institutions, we continuously enrich and expand the BreathBase database, now the largest breath profile repository globally, with over 160,000 patient profiles (including clinical data) across diseases such as asthma, Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Disease (ILD), Cystic Fibrosis (CF), transplant patients, lung cancer and various other cancers.
These partnerships empower us to refine and optimize the diagnostic biomarkers within the BreathBase Platform, ensuring the highest level of precision and personalization in disease diagnosis, phenotype identification, and therapy prediction. By working closely with these esteemed institutions, we not only accelerate innovations in breath diagnostics but also ensure that our clinical partners have access to the latest advancements in precision diagnostics, optimizing both research quality and potentially patient outcomes.
Developed through close clinical collaboration, our eNose technology works seamlessly with BreathBase, enabling three transformative applications: early diagnosis, precision medicine, and therapy response monitoring. Supported by pattern recognition algorithms and an extensive reference database, each application has the potential to deliver rapid, personalized, and data-driven insights that can transform patient care.
(Early) Diagnosis
The BreathBase® Solution holds great promise for early diagnosis across a wide range of diseases, including various forms of cancer, inflammatory conditions, metabolic disorders, and infectious diseases. By analyzing unique breath profiles, our technology aims to detect subtle metabolic changes before clinical symptoms appear. Ongoing studies suggest that this non-invasive approach could provide an efficient tool for early detection, supporting clinicians in identifying diseases at an earlier stage, ultimately improving patient outcomes and reducing healthcare costs.
Precision Medicine
With precision medicine, the BreathBase® Solution could play a pivotal role in personalizing treatment plans. By capturing and analyzing volatile organic compounds (VOCs) in the breath, our platform has the potential to identify specific disease subtypes and patient phenotypes. This information can be used to tailor treatments, for example in diseases like cancer, COPD, and asthma, where patient responses can vary widely. Our ongoing research aims to refine these predictive models, contributing to more targeted and effective therapies.
Therapy response
Monitoring therapy response is crucial in optimizing patient care. The BreathBase® Solution may offer a novel way to assess the effectiveness of treatments in real time. By continuously evaluating changes in breath profiles, we can provide valuable insights into patient responses, whether in cancer immunotherapy, antibiotic treatments, or chronic disease management. This non-invasive method could help clinicians quickly adjust therapies based on objective data, improving treatment efficacy and patient outcomes.
Global Clinical partners
In collaboration with renowned institutions worldwide, we are pushing the boundaries of breath diagnostics research. The organizations shown here represent just a selection of our valued partners.
Building the Future of Patient-Centered Diagnostics
At Breathomix, our mission is to rigorously explore and optimize the many applications of the BreathBase Solution, ultimately bringing eNose technology to patients. As we work towards clinical implementation, we remain dedicated to close partnerships with clinical centers. Every high-quality breath profile added to BreathBase enriches our reference database and enhances the precision of our diagnostic insights. With over 25 ongoing projects—including early detection of rejection in transplant patients—we are committed to advancing breath diagnostics and expanding its potential to benefit patients worldwide.